Let's talk medical research

We’re thrilled to share that our CEO, Laurent Schockmel, has been named a top 40 Healthcare Transformer by Medical Marketing & Media (MM&M). This honor is given to visionaries driving innovation at the intersection of healthcare and technology, and it’s exciting to see Laurent in such great company. Laurent took the helm as CEO of Antidote in 2018 with the objective of harnessing our ...

At Antidote, we talk a lot about how our search tool makes it easier to match with clinical trials you may qualify for. But what happens after you conduct your search?

It's an exciting time to consider participating in Parkinson's research, says Katie Kopil, PhD, Director of Research Partnerships at The Michael J. Fox Foundation for Parkinson's Research (MJFF).

Antidote recently conducted a survey with SCORR Marketing through which we asked nearly 4,000 patients about their perspectives on clinical trials. One key finding: patients with different conditions have different opinions on taking part in medical research. For example, in the survey, people with melanoma were joining clinical trials to extend their own lives, while those with lupus or kidney ...

Last week we distributed a white paper on precision recruitment, a new approach that not only speeds up clinical trial recruitment, but also provides a better patient experience throughout the recruitment process. Now, we're inviting you to join a webinar on March 28th at 12pm, during which we will be diving deeper into this topic.

Chronic kidney disease (CKD) is one of the top-ten causes of death in the United States – but 96% of people in its early stages don't even know they have it.

With medicine getting ever more targeted and precise, clinical trial protocols are becoming more complex than ever before. While this allows for appropriate evaluation of potential treatment options, it also means that finding patients to take part in trials is increasingly challenging, and the need to look beyond traditional methods of recruitment has become clear.

During a Q3 2018 survey conducted by Antidote Technologies and SCORR Marketing, we explored specific participation stimuli to determine what could make patients consider participating in a clinical trial – and how these motivations varied by condition area.

There are conferences we attend to connect with clients. There are conferences we attend to build partnerships. At SCOPE, we are able to do both. The SCOPE Summit convenes the best, the brightest, and the most dedicated in the clinical trial operations space with one aim: to accelerate clinical research. This is why we go to SCOPE.

Pulmonary hypertension (PH) is a type of high blood pressure in the lungs. A rare disease, PH is often misdiagnosed as asthma or COPD. Unfortunately, delays in diagnosis mean delays in treatment; sometimes, patients aren't diagnosed until they're in late stage disease – and by then, they have limited options.